KRAS-mutant cancer cells could become adaptive to glutamine depletion through asparagine biosynthesis by ASNS; pronounced growth suppression was observed upon ASNS knockdown, indicating that ASNS might be a novel therapeutic target against tumors with mutated KRAS [85]. This evidence concerns the gene KRAS and cancer.